Found: 4
Select item for more details and to access through your institution.
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 3, p. 256, doi. 10.1159/000533650
- By:
- Publication type:
- Article
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
- Published in:
- Molecular Therapy, 2015, v. 23, n. 9, p. 1532, doi. 10.1038/mt.2015.109
- By:
- Publication type:
- Article
Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients.
- Published in:
- Molecular Therapy, 2015, v. 23, n. 3, p. 602, doi. 10.1038/mt.2014.243
- By:
- Publication type:
- Article
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
- Published in:
- Nature, 2011, v. 477, n. 7362, p. 99, doi. 10.1038/nature10358
- By:
- Publication type:
- Article